Wells Fargo raised the firm’s price target on Rapt Therapeutics (RAPT) to $72 from $48 and keeps an Overweight rating on the shares. Following its key opinion leader webinar and channel check on RPT904 CSU data and opportunity in food allergy and chronic spontaneous urticaria, the firm highlights its experts’ positive view on RPT904’s differentiation and future adoption even with the advent of Xolair biosimilars.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics price target raised to $72 from $27 at H.C. Wainwright
- Clear Street positive on Rapt Therapeutics into food allergy study
- Rapt Therapeutics initiates prestIgE Phase 2b trial
- Rapt Therapeutics initiated with a Buy at Guggenheim
- Rapt Therapeutics Advances Food Allergy Treatment with RPT904 Study